Loading patent…
OwnerMaría Dolores MAYÁN SANTOS, Adrián VARELA VÁZQUEZ +6inventors
InventorsMaría Dolores MAYÁN SANTOS, Adrián VARELA VÁZQUEZ, Amanda GUITIÁN CAAMAÑO, Paula CARPINTERO FERNÁNDEZ, Marta VARELA EIRÍN, Eduardo FONSECA CAPDEVILA, María QUINDÓS VARELA, Teresa CALLEJA CHUCLA
Estimating the term…
The present invention refers to Cx43, preferably in combination with an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK, for use in the treatment of cancer wherein the cancer is characterized by the activation of mitogen-activated protein kinase (MAPK) selected from the list consisting of: BRAF, RAS, MEK or ERK.
A method of treating cancer in a subject in need thereof, wherein the cancer is characterized by the activation of a mitogen-activated protein kinase (MAPK) selected from the group consisting of:
A combination drug product comprising Connexin 43 and an inhibitor of a mitogen-activated protein kinase (MAPK) selected from the group consisting of:
Dependencies are inferred from the claim text.